Thymosin Alpha-1: What the Research Shows
For laboratory and research use only. This article summarises published scientific research on Thymosin Alpha-1. Neurovia’s Thymosin Alpha-1 is not intended for human consumption. See our disclaimer.
Thymosin Alpha-1: What the Research Shows
Thymosin Alpha-1 (Tα1) is a naturally occurring peptide derived from the thymus gland with one of the most extensively published research histories of any immunomodulatory peptide. Originally isolated from thymic tissue in the 1970s, it has progressed through preclinical research, clinical trials, and pharmaceutical approval in multiple countries — making it an unusually well-characterised research compound with a deep published literature.
This article provides an evidence-based overview of Thymosin Alpha-1: its molecular identity, the published research landscape, its studied immune system interactions, and supply format for laboratory use.
What Is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino acid peptide originally isolated from Thymosin Fraction 5 — a bovine thymic extract studied by Allan Goldstein and colleagues at George Washington University beginning in the late 1960s. The isolation and characterisation of Tα1 as the primary active component of Thymosin Fraction 5 was published by Goldstein et al. in Proceedings of the National Academy of Sciences in 1977.
Molecular profile:
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
- Length: 28 amino acids
- N-terminal acetylation (Ac-Ser)
- Molecular weight: ~3108 Da
- CAS Number: 62304-98-7
- Pharmaceutical name: Thymalfasin
Thymosin Alpha-1 is one of the few research peptides that has received regulatory approval as a pharmaceutical in multiple countries. It is approved in Italy (as Zadaxin, by SciClone Pharmaceuticals) and in China, primarily for use in hepatitis and immunocompromised patient contexts. It has not received FDA approval in the United States, where it remains a research compound.
The Published Research Landscape
The published research on Thymosin Alpha-1 is exceptionally broad, spanning preclinical immunology, virology, oncology, and clinical trial data. This depth of literature distinguishes it from many other research peptides.
Immune System Research
The foundational and most extensively published research on Tα1 concerns its studied interactions with the immune system. Published research has examined:
T-cell biology — Tα1 was originally characterised as a thymic hormone involved in T-cell maturation and differentiation. Published preclinical studies have examined its studied effects on T-cell subset development, activation, and cytokine production in cell culture and animal models.
Dendritic cell research — Published studies have investigated Tα1’s interactions with dendritic cell maturation and antigen presentation, proposing a mechanism by which it may enhance adaptive immune responses in preclinical models.
Toll-like receptor (TLR) research — A more recent body of published research has examined Tα1’s interactions with TLR signalling pathways, particularly TLR9, in the context of innate immune activation. This work has been published in journals including Blood and Journal of Immunology.
NK cell research — Some published studies have examined Tα1’s relationship with natural killer (NK) cell activity in animal models and cell culture.
Viral Research
A substantial body of published research has examined Thymosin Alpha-1 in viral infection contexts in animal models and clinical settings:
Hepatitis B and C research — The most extensively published clinical research on Tα1 concerns its studied role as an adjunct in hepatitis B and C treatment. Multiple published clinical trials have examined Tα1 in combination with interferon in hepatitis contexts, with work published in journals including Hepatology and Journal of Hepatology.
HIV research — Published clinical and preclinical studies have examined Tα1 in HIV-related immune dysfunction contexts.
Sepsis research — A growing published literature has examined Tα1 in sepsis and critical illness contexts, with clinical studies from China reporting its use in intensive care settings.
Oncology Research
Published preclinical and clinical research has examined Thymosin Alpha-1 as an immunological adjunct in oncology contexts, studying its interactions with tumour-associated immunity in animal models and its combination with conventional treatments in clinical research settings.
Mechanism of Action
The mechanisms through which Thymosin Alpha-1 exerts its studied immune effects are not completely characterised in the published literature, but several pathways have been proposed and investigated:
TLR9 agonism — Published research from Romani and colleagues (published in Blood, 2006) proposed that Tα1 signals through TLR9, activating plasmacytoid dendritic cells and driving interferon-alpha production. This represents one of the most mechanistically specific published proposals for Tα1’s mode of action.
T-cell receptor signalling enhancement — Earlier published research proposed that Tα1 enhances T-cell receptor signal transduction, potentially through effects on intracellular signalling cascades downstream of TCR activation.
Cytokine modulation — Multiple published studies have reported changes in cytokine profiles (including IL-2, IFN-γ, and TNF-α) in Tα1-treated animal models and cell cultures, though the precise mechanism of these effects remains under investigation.
Thymosin Alpha-1 vs Thymosin Beta-4 (TB-500)
These are two distinct peptides from the thymosin family that are frequently confused:
| Thymosin Alpha-1 | Thymosin Beta-4 (TB-500) | |
|---|---|---|
| Origin | Thymosin Fraction 5 | Thymosin Fraction 5 |
| Length | 28 amino acids | 43 amino acids |
| Primary research focus | Immune modulation | Actin sequestration, tissue repair |
| Regulatory status | Approved in Italy/China | Research compound only |
| Primary mechanism | TLR9, T-cell biology | G-actin binding (LKKTET motif) |
Both are derived from the thymus-related thymosin protein family but have entirely different structures, mechanisms, and research contexts.
Supply Format for Research
Neurovia supplies:
- Thymosin Alpha-1 10mg — lyophilised vial for laboratory research
Supplied at 99% purity, third-party tested, with Certificate of Analysis available.
Storage: lyophilised at -20°C long-term; 2–8°C short-term. Once reconstituted, refrigerate and use within 4 weeks.
Further reading: peer-reviewed research on Thymosin Alpha-1 (PubMed).
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from bovine thymic tissue by Allan Goldstein’s group in 1977. It has been extensively studied in immune modulation, viral, and oncology research contexts, and holds pharmaceutical approval (as Thymalfasin/Zadaxin) in Italy and China.
What is Thymosin Alpha-1 research peptide?
In research contexts, Thymosin Alpha-1 is studied as an immunomodulatory compound, with published research examining its interactions with T-cells, dendritic cells, TLR9 signalling, and NK cell activity in preclinical models and clinical trials.
What are Thymosin Alpha-1 studies?
Published Thymosin Alpha-1 studies span preclinical immunology, hepatitis clinical trials, HIV research, sepsis studies, and oncology adjunct research. It is one of the most clinically researched peptides outside the growth hormone and GLP-1 classes, with publications in top-tier immunology and hepatology journals.
What is the difference between Thymosin Alpha-1 and Thymosin Beta-4?
They are distinct peptides from the same thymosin family. Thymosin Alpha-1 (28 aa) is studied for immune modulation and has pharmaceutical approval. Thymosin Beta-4/TB-500 (43 aa) is studied for actin sequestration and tissue repair. They have different sequences, mechanisms, and research contexts.
What is immune modulation with Thymosin Alpha-1?
Published research has studied Tα1’s ability to modulate immune responses through several proposed mechanisms — TLR9 activation, T-cell biology, and cytokine profile changes in preclinical models and clinical settings. The most mechanistically specific published proposal involves TLR9 signalling in plasmacytoid dendritic cells (Romani et al., Blood, 2006).
Is Thymosin Alpha-1 approved as a pharmaceutical?
Yes — Thymosin Alpha-1 (Thymalfasin/Zadaxin) is approved as a pharmaceutical in Italy and China for specific indications. It is not FDA-approved in the United States, where it is classified as a research compound.
This article summarises published peer-reviewed research on Thymosin Alpha-1 and is provided for informational purposes only. Neurovia’s Thymosin Alpha-1 is supplied for laboratory research use only and is not intended for human consumption. Full disclaimer →
Related Reading
For the manufacturing and sourcing standards behind a compound with this depth of published research, see GMP Versus Non GMP Peptides and Quality.